|
¾ÆÇǸÞÁî |
ÀǾàÇ° ºÐ¼®¿¬±¸ ÆÀ¿ø ä¿ë
¼¿ï ±Ýõ±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
3³â¡è |
ä¿ë½Ã |
08.09 |
|
|
µ§Ã÷ÇöóÀÌÄÚ¸®¾Æ |
[¿Ü±¹°è] Ä¡°ú ±³Á¤ÀåÄ¡ ¿µ¾÷ Clinical Sales
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
05.17 |
|
|
(ÁÖ)¸Þµð¼¾¼ |
(ÁÖ)¸Þµð¼¾¼ ÄÚ½º´Ú °ü°è»ç ȸ°è °á»ê/ ¼¼¹«/ ¿ø°¡ ´ã´çÀÚ
´ë±¸ ´Þ¼±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
À繫/ȸ°è/IR/ÀÚ±Ý/°¨»ç |
3³â¡è |
ä¿ë½Ã |
05.20 |
|
|
(ÁÖ)Ä«µð¿ÀÅØ |
ÀÇ·á±â±â QA, QC °ü¸®ÀÚ, ´ã´çÀÚ ¸ðÁý
¼¿ï Á߶û±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
3³â¡è |
ä¿ë½Ã |
10.27 |
|
|
(ÁÖ)¸Þµð½êÀÌ |
(ÁÖ)¸Þµð½êÀÌ À繫 ȸ°è´ã´çÀÚ
°æ±â ÀÇÁ¤ºÎ½Ã | Çз¹«°ü |
À繫/ȸ°è/IR/ÀÚ±Ý/°¨»ç |
3³â¡è |
»ó½Ãä¿ë |
06.18 |
|
|
(ÁÖ)ÄɾîÅØ |
(ÁÖ)ÄɾîÅØ ±â¼ú¿¬±¸¼Ò ¿¬±¸¿ø ¸ðÁý
°¿ø ¿øÁֽà | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
3³â¡è |
ä¿ë½Ã |
07.19 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Quality Associate / fixed term until 202
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
3³â¡è |
ä¿ë½Ã |
02.25 |
|
|
ÈÞÁ©(ÁÖ) |
[ÀÇÇÐÁ¤º¸ÆÀ] MIS °æ·Â
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
2³â¡è |
»ó½Ãä¿ë |
07.11 |
|
|
Å©·¹³Ê ÇコÄɾî |
Å©·¹³Ê MIS(Medical Information Service) ¾à»ç ±¸ÀÎ
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
2³â¡è |
ä¿ë½Ã |
06.12 |
|
|
°æ³²Á¦¾à |
ÀǾàÇ°°³¹ßÆÀ °æ·ÂÁ÷ ±¸ÀÎ
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
2³â¡è |
ä¿ë½Ã |
08.01 |
|
|
ICON Clinical Research Korea |
Study Start-up Associate
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.22 |
|
|
¢ß¹ÙÅØÄÚ¸®¾Æ |
¢ß¹ÙÅØÄÚ¸®¾Æ CAD/CAM ½Ã½ºÅÛÀ¯Áö°ü¸®ÆÀ °æ·Â (ºÎ»ê,°æ³² Áö
¼¿ï ¿ë»ê±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¹«¿ª/ÇØ¿Ü¿µ¾÷/Åë¹ø¿ª |
2³â¡è |
ä¿ë½Ã |
02.28 |
|
|
(ÁÖ)¸ÞµðÇïÇÁ¶óÀÎ |
Clinical QA Team(Ç°Áúº¸Áõ) °æ·Â»ç¿ø ¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
2³â¡è |
ä¿ë½Ã |
11.17 |
|
|
Çѱ¹¾á¼¾ |
[Janssen] Medical Advisor - Solid Tumor Targeted Therapy
¼¿ï ¿ë»ê±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ó¹Ý±â »ç¿ø¸ðÁý |
2³â¡è |
ä¿ë½Ã |
03.08 |
|
|
ICON Clinical Research Korea |
Jr. Clinical Research Associate(Oncology)
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.22 |
|